DC positions
DC1 Innovative genomic technologies for the advanced characterization of myotonic dystrophy mutations
Genartis, Italy
DC2 The complexity of DM repeat expansions: new challenges in developing personalized molecular therapeutics (WP1).
Host institution: UTOV, Italy
DC3 A new integrated in vitro platform to study DM muscle disease (WP1).
Host institution: IBEC, Spain
DC4 Advanced human 3D neuromuscular and cortical models for mechanistic and therapeutic research (WP1).
Host institution: CECS, France
DC5 Structure and dynamics of nuclear RNA foci in myotonic dystrophy type 1 and 2 (WP1)
Host institution: RUMC, the Netherlands
DC6 The contribution of miRNome alterations to DM1: beyond the Muscleblind sequestration model (WP1).
Host institution: UVEG, Spain
DC7 Rescuing disrupted single-cell and neural network activities in human DM neural models using ASO (WP2)
Host institution: RUMC, the Netherlands
DC8 Therapeutical potential of ASO inducing skipping of CUGexp-containing exon in myotonic dystrophy (WP2)
Host institution: AMU, Poland
DC9 Enhancing the activity of therapeutic ASO by genetic modulation and sequence motif adjuvants (WP2).
Host institution: UVEG, Spain
DC10 Novel ASO molecules for the therapy of DM1 (WP2)
Host institution: CSIC, Spain
DC11 Development of circulating muscle-specific biomarkers (WP3)
Host institution: INSERM, France
DC12 Circulating biomarkers of brain dysfunction in DM1 (WP3)
INSERM, France
DC13 Myotonic Dystrophy Type 2 (DM2): Biomarker discovery and correlation to clinical outcomes (WP3)
LMU, Germany
DC14 Participation in clinical trials: the contribution of decision-making cognition in patients with DM1 (WP3)
UPC, France
